

# CITATION REPORT

List of articles citing

Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial

DOI: 10.7326/0003-4819-119-11-199312010-00002  
Annals of Internal Medicine, 1993, 119, 1067-71.

**Source:** <https://exaly.com/paper-pdf/24446844/citation-report.pdf>

**Version:** 2024-04-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
107	Control of Rheumatoid Disease as a Requisite for Successful Outcome of Rehabilitation. <b>1994</b> , 5, 663-684		1
106	Second-line drug therapy for rheumatoid arthritis. <b>1994</b> , 330, 1368-75		136
105	Hydroxychloroquine and pain thresholds. <b>1995</b> , 38, 445-6		2
104	A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. <b>1995</b> , 98, 156-68		121
103	Antimalarial Drugs. <b>1995</b> , 4, 219-234		5
102	Disease-modifying antirheumatic drugs. Potential effects in older patients. <b>1995</b> , 7, 420-37		21
101	Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. <b>1996</b> , 347, 347-52		102
100	Cytokine-Suppressive Anti-Inflammatory Drugs. <b>1996</b> , 6, 395-404		1
99	The role of anti-malarials in rheumatoid arthritis [the American experience. <b>1996</b> , 5, 41-44		13
98	Ophthalmologic considerations in using antimalarials in the United States. <b>1996</b> , 5, 73-74		24
97	The use of antimalarials in combination with other disease modifying agents in RA [the British experience. <b>1996</b> , 5, 50-58		6
96	Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. <b>1996</b> , 25, 421-8		51
95	Treatment of rheumatoid arthritis. <b>1997</b> , 81, 57-84		9
94	Rheumatoid Arthritis. <b>1997</b> , 1, 141-153		5
93	The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. <b>1997</b> , 29, 127-50		90
92	Minocycline in rheumatoid arthritis. <b>1997</b> , 40, 794-6		15
91	Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. <b>1999</b> , 64, 325-35		32

90	Remodeling the therapeutic pyramid: evolving therapeutic strategies for rheumatoid arthritis. <b>1999</b> , 9, 1-16	
89	Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. <b>1999</b> , 42, 357-65	66
88	Rheumatoid Arthritis. <b>2000</b> , 674-685	4
87	Antimalarials for treating rheumatoid arthritis. <b>2000</b> ,	13
86	Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. <b>2000</b> , 59, 468-77	47
85	[Treatment of rheumatoid arthritis]. <b>2000</b> , 114, 777-83	
84	Macrophages in rheumatoid arthritis. <b>2000</b> , 2, 189-202	565
83	Pharmacotherapy of rheumatoid arthritis: an overview. <b>2001</b> , 62, 92-112	11
82	A clinical and economic review of disease-modifying antirheumatic drugs. <b>2001</b> , 19, 715-28	27
81	Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. <b>2001</b> , 8, 123-43	36
80	Guidelines for the management of rheumatoid arthritis: 2002 Update. <b>2002</b> , 46, 328-46	1135
79	Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. <b>2002</b> , 46, 1460-9	169
78	Pharmacological treatment of established rheumatoid arthritis. <b>2003</b> , 17, 811-29	22
77	Methotrexate versus chloroquine in the treatment of rheumatoid arthritis. <b>2003</b> , 6, 26-31	1
76	Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives?. <b>2003</b> , 20, 723-36	28
75	Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. <b>2004</b> , 34, 182-6	83
74	Treatment of Rheumatoid Arthritis in the Elderly. <b>2005</b> , 35, 151-154	
73	Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. <b>2005</b> , 21, 649-69, viii	9

72	[Antimalarials: an update in rheumatic diseases]. <b>2006</b> , 2, 190-201	8
71	Rheumatoid Arthritis. <b>2006</b> ,	
70	Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study. <b>2006</b> , 25, 557-9	4
69	Response to intramuscular methyl prednisolone in inflammatory hand pain: evidence for a targeted clinical, ultrasonographic and therapeutic approach. <b>2007</b> , 66, 690-2	9
68	Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. <b>2007</b> , 33, 197-217	32
67	Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials. <b>2007</b> , 5, 3	53
66	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <b>2008</b> , 59, 762-84	1118
65	Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. <b>1995</b> , 102, 144-51	39
64	Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. <b>2008</b> , 30, 930-40	36
63	What have we learnt about the development and progression of early RA from RCTs?. <b>2009</b> , 23, 13-24	5
62	Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?. <b>2009</b> , 61, 1284-6	3
61	Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. <b>2009</b> , 26, 273-93	19
60	The older rheumatoid arthritis patients: who are they and how should they be treated?. <b>2010</b> , 6, 533-549	1
59	The effects of disease modifying anti-rheumatic drugs on osteoclastogenesis and bone destruction in rheumatoid arthritis. <b>2011</b> , 34, 493-500	3
58	Hydroxychloroquine: from malaria to autoimmunity. <b>2012</b> , 42, 145-53	348
57	Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial. <b>2013</b> , 14, 64	20
56	Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. <b>2013</b> , 33, 1105-20	19
55	Guidelines for the drug treatment of rheumatoid arthritis. <b>2013</b> , 53, 158-183	1

54	Diretrizes para o tratamento da artrite reumatoide. <b>2013</b> , 53, 158-183	16
53	Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis. <b>2013</b> , 9, 969-81	
52	Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. <b>2013</b> , 68, 766-71	97
51	Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection. <b>2014</b> , 58, 584-6	8
50	Pharmacology of Chloroquine and Hydroxychloroquine. <b>2014</b> , 35-63	65
49	Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. <b>2015</b> , 14, 358-62	84
48	Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine. <b>2015</b> , 128, 449-64	23
47	Anti-malarials: Are There Benefits Beyond Mild Disease?. <b>2016</b> , 2, 1-12	5
46	Discoveries of conventional synthetic disease modifying anti-rheumatic drugs Serendipity or flawless reasoning?. <b>2016</b> , 11, 32-38	3
45	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <b>2017</b> , 65, 17-24	58
44	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2017</b> , 958-982.e7	2
43	Use of En Face Optical Coherence Tomography in a Case of Hydroxychloroquine Retinal Toxicity. <b>2018</b> , 2, 51-57	
42	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. <b>2018</b> , 12, 1685-1695	53
41	Inflammatory arthritis in systemic sclerosis: What to do?. <b>2019</b> , 4, 3-16	2
40	Update on novel pharmacological therapies for osteoarthritis. <b>2019</b> , 11, 1759720X19864492	41
39	Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. <b>2019</b> , 38, 3331-3350	11
38	Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis. <b>2020</b> , 11, 562777	7
37	Risk factors and electrocardiogram characteristics for mortality in critical inpatients with COVID-19. <b>2020</b> , 43, 1624-1630	18

36	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. <b>2020</b> , 46, 574-578	8
35	Hydroxychloroquine safety: A meta-analysis of randomized controlled trials. <b>2020</b> , 36, 101812	12
34	Prospects for Therapies in Osteoarthritis. <b>2021</b> , 109, 339-350	18
33	Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review. <b>2020</b> , 83, 563-578	47
32	Hydroxychloroquine and COVID-19. <b>2020</b> , 96, 550-555	77
31	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. <b>2021</b> , 77, 13-24	9
30	Efficacy and safety of hydroxychloroquine in osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. <b>2021</b> ,	1
29	Ethical dimensions in randomized trials and off-label use of investigational drugs for COVID-19 treatment. 147775092110114	0
28	Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. <b>2021</b> , 334, 129663	4
27	A systematic review and meta-analysis of the safety of Hydroxychloroquine in a randomized controlled trial and observational studies. <b>2021</b> ,	
26	Cost-effectiveness of hydroxychloroquine placebo for hand osteoarthritis: economic evaluation of the HERO trial.. <b>2021</b> , 10, 821	1
25	Hydroxychloroquine. <b>2005</b> , 81-92	5
24	Rheumatic Diseases. <b>2006</b> , 1383-1408	2
23	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2013</b> , 917-940.e6	2
22	MEDICAL ASPECTS OF RHEUMATOID ARTHRITIS. <b>1996</b> , 12, 463-475	6
21	Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. <b>2020</b> ,	5
20	The VR23 Antitumor Compound Also Shows Strong Anti-Inflammatory Effects in a Human Rheumatoid Arthritis Cell Model and Acute Lung Inflammation in Mice. <b>2020</b> , 204, 788-795	4
19	CURRENT CONCEPTS REGARDING PHARMACOLOGIC TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS. <b>2001</b> , 17, 321-338	2

18 Pharmakotherapie. **2007**, 129-174

17 Rheumatoid Arthritis. **2009**, 1025-1038

1

16 Other Traditional Disease-Modifying Antirheumatic Drugs: Monotherapy and Combination Therapy. **2009**, 325-336

15 Disease-Modifying Antirheumatic Drug Use in Older Rheumatoid Arthritis Patients. **2011**, 151-172

14 Rheumatoid Arthritis. **2018**, 731-741

13 Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. **2021**, 10, 294

0

12 Targeting lysosomes in human disease: from basic research to clinical applications. **2021**, 6, 379

7

11 Rheumatische Erkrankungen. **2004**, 367-388

10 Historical and Current Perspectives on Management of Osteoarthritis and Rheumatoid Arthritis. **2008**, 5-36

1

9 Rheumatische Erkrankungen. **2007**, 355-370

8 Rheumatoid arthritis. **2007**, 2007,

1

7 DataSheet\_1.pdf. **2020**,

6 DataSheet\_2.pdf. **2020**,

5 Synthesis of Reduced Graphene Oxide by Ethyl Acetate and Its Utilization in Determining Hydroxychloroquine in Wastewater and Pharmaceutical Samples. **2022**, 7,

0

4 Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. **2022**, 14, 2551

0

3 Biotransformation of hydroxychloroquine to evaluate the cytotoxicity of its metabolites and mimic mammalian metabolism. **2023**, 5, 100761

0

2 Emerging role of macrophages in non-infectious diseases: An update. **2023**, 161, 114426

1

1 Ocular microvascular alteration in Sjögren's syndrome treated with hydroxychloroquine: an OCTA clinical study. **2023**, 14, 204062232311644

0

